[
  {
    "ts": null,
    "headline": "Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report",
    "summary": "Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its obesity drug Wegovy. As rival Eli Lilly and Co.’s (NYSE:LLY) Zepbound gains momentum, the Danish pharmaceutical giant is ...",
    "url": "https://finnhub.io/api/news?id=78f4dffa541d3e99285e9d7b770d00d307cc699b748b9fbffe8c52de80295109",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751567431,
      "headline": "Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report",
      "id": 135742903,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its obesity drug Wegovy. As rival Eli Lilly and Co.’s (NYSE:LLY) Zepbound gains momentum, the Danish pharmaceutical giant is ...",
      "url": "https://finnhub.io/api/news?id=78f4dffa541d3e99285e9d7b770d00d307cc699b748b9fbffe8c52de80295109"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Staring at Tremendous Opportunity in Alzheimer Market: RBC Capital Markets",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC Capital Markets reiterated that the company’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock significant value in the Alzheimer’s treatment market. The research firm is optimistic that the trial will deliver positive results, […]",
    "url": "https://finnhub.io/api/news?id=050cf13f1cf3827b07c178fb844cd0f8aa98ce3c1db7e07f435944238e6419a1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751548766,
      "headline": "Eli Lilly (LLY) Staring at Tremendous Opportunity in Alzheimer Market: RBC Capital Markets",
      "id": 135735488,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC Capital Markets reiterated that the company’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock significant value in the Alzheimer’s treatment market. The research firm is optimistic that the trial will deliver positive results, […]",
      "url": "https://finnhub.io/api/news?id=050cf13f1cf3827b07c178fb844cd0f8aa98ce3c1db7e07f435944238e6419a1"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Trades Above 50-Day Average for a Month: Time to Buy?",
    "summary": "PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.",
    "url": "https://finnhub.io/api/news?id=a20a7d6e358ca1e63f0b7870ff6a32bb9b0c5b0baf6b2371d041d1915b3e3d71",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751546880,
      "headline": "Pfizer Trades Above 50-Day Average for a Month: Time to Buy?",
      "id": 135735489,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.",
      "url": "https://finnhub.io/api/news?id=a20a7d6e358ca1e63f0b7870ff6a32bb9b0c5b0baf6b2371d041d1915b3e3d71"
    }
  },
  {
    "ts": null,
    "headline": "Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth",
    "summary": "LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.",
    "url": "https://finnhub.io/api/news?id=360d9ba1a355d3457eb618cc67af06143082c0c6ea67ffb8c98a8ea48247c5bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751545200,
      "headline": "Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth",
      "id": 135735490,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.",
      "url": "https://finnhub.io/api/news?id=360d9ba1a355d3457eb618cc67af06143082c0c6ea67ffb8c98a8ea48247c5bf"
    }
  }
]